Dmitri Souza
Pain Medicine · Cuyahoga Falls, OHNPI 1578718821
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,809 of the $60,562 with a category attached, or 95.5%. AbbVie accounts for 97.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $23,176 and has fallen 77.8% since, to $5,148 in 2025. Among pain medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $406.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$59K
- Stimwave Technologies Incorporated$325
- Medtronic$209
- Pfizer$153
- Nevro Corp.$128
- Collegium Pharmaceutical, Inc.$116
- plus $821 from 20 others
Across 5 payments — averaging $5896.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Scilex Pharmaceuticals Inc.$29K
What the payments were for
- Speaking & faculty fees$57,80995%
- Food & beverage$2,7204%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 82 | $58,810 |
| Stimwave Technologies Incorporated | 2 | $325 |
| Medtronic | 2 | $209 |
| Pfizer | 9 | $153 |
| Nevro Corp. | 2 | $128 |
| Collegium Pharmaceutical, Inc. | 7 | $116 |
| Averitas Pharma Inc. | 4 | $93 |
| Lilly USA, LLC | 6 | $83 |
| Lundbeck LLC | 4 | $81 |
| Abbott | 4 | $66 |
| Vertex | 3 | $62 |
| GRT US Holding, Inc. | 3 | $61 |
| SPR Therapeutics, Inc | 1 | $58 |
| Amgen | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| Assertio Therapeutics, Inc. | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Johnson & Johnson | 1 | $26 |
| Boston Scientific | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Nalu Medical, Inc. | 1 | $17 |
| Curonix LLC | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $12 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| MDD US Operations, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$51,488
- QULIPTA$20,344
- SYNCHROMEDII$186
- Senza$108
How this compares
$60,562 in reported general payments places this provider in the 95th percentile of 245 pain medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 164 | $32,649 |
| BelbucaBuprenorphine Hcl | 57 | $28,164 |
| QuliptaAtogepant | 11 | $14,350 |
| Pregabalin | 239 | $5,450 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 242 | $4,464 |
| Lidocaine | 37 | $3,857 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 177 | $2,558 |
| Gabapentin | 250 | $2,545 |
| Naloxone Hcl | 32 | $1,736 |
| Lidocaine Hcl | 13 | $1,628 |
| Duloxetine Hcl | 123 | $1,575 |
| Oxycodone Hcl | 71 | $854 |
| Celecoxib | 28 | $840 |
| Topiramate | 48 | $786 |
| Baclofen | 63 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $116 | $28,16457 claims |
| AbbVieQulipta | $58,810 | $14,35011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 245 pain medicine providers in Ohio.
Other pain medicine in Cuyahoga Falls
- Alexander EscobarToledo$638K
- Nagy MekhailCleveland$511K
- Henry VuceticWilloughby$509K
- Tammy DannDayton$431K
- Michael DankoLoveland$381K
- Jonathan SilvermanDayton$234K
- Tristan WeaverColumbus$202K
- Robert BolashCleveland$154K
- Aman UpadhyayCleveland$40K
- Salim HayekCleveland$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.